ProCE Banner Activity

How I Manage Patients With Locally Advanced, Unresectable Bladder Cancer

Clinical Thought
Best practices for treating unresectable, locally advanced bladder cancer continue to evolve. Read my thoughts on tailoring treatment based on specific patient and disease characteristics in this setting.

Released: December 01, 2017

Expiration: November 30, 2018

No longer available for credit.

Share

Faculty

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Clovis, Exelixis, Genentech, Horizon Pharma, Inovio, Lilly, Novartis, and Pfizer and funds for research support from Astellas, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Peloton, and Pfizer (paid to her institution).